Prognostic Value of the Pretreatment Global Immune–Nutrition–Inflammation Index in Nasopharyngeal Carcinoma: A Multicenter Retrospective Cohort Study


Creative Commons License

Aksoy A., Aydın A. A., Karatas T. D., Yüceer R. O., Uçar M., Yücel B.

MEDICINA (KAUNAS, LITHUANIA), cilt.62, sa.11, ss.1-14, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 62 Sayı: 11
  • Basım Tarihi: 2026
  • Doi Numarası: 10.3390/medicina62112250
  • Dergi Adı: MEDICINA (KAUNAS, LITHUANIA)
  • Derginin Tarandığı İndeksler: Health Research Premium Collection (ProQuest), Scopus, Science Citation Index Expanded (SCI-EXPANDED), EMBASE, MEDLINE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.1-14
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

Background and Objectives: Nasopharyngeal carcinoma (NPC) exhibits substantial biological heterogeneity that is not fully captured by TNM staging. We investigated the prognostic significance of the pretreatment Global Immune–Nutrition–Inflammation Index (GINI) in NPC. Materials and Methods: This multicenter retrospective cohort study included 96 patients with pathologically confirmed NPC who were treated between 2015 and 2024. GINI was calculated using neutrophil, lymphocyte, monocyte, and platelet counts, along with serum C-reactive protein and albumin levels. The optimal cutoff was identified by receiver operating characteristic analysis. Survival outcomes were assessed with Kaplan–Meier and multivariable Cox regression analyses. Results: The optimal GINI cutoff was 3403 (AUC: 0.726, p < 0.001), which showed a numerically higher AUC than the neutrophil-to-lymphocyte ratio (NLR; AUC: 0.674, p = 0.003). High GINI was associated with advanced stage (p = 0.008), shorter overall survival (OS) (23 vs. 95 months, p < 0.001), and shorter disease-free survival (DFS) (16 vs. 95 months, p < 0.001). In multivariable analysis, high GINI remained significantly associated with poorer OS and DFS. Conclusions: Pretreatment GINI was strongly associated with survival in patients with NPC and may serve as a useful adjunctive prognostic marker. Further prospective studies and external validation are required before its incorporation into clinical risk-stratification strategies.